EGFR and neoplasm: Sandra et al. constructed a dual-specific antibody, BiTE, which could target both EGFR of tumor cells and CD3 of T cells, and infused this BiTE into T cells, resulting in no attacks on normal tissues while locally killing tumor cells, indicating that this BiTE CAR T could well attenuate off-target effects [75].